December 22, 2003

Dutch supreme court sustains Immunomedics patent

December 8, 2003

Multiple presentations on Immunomedics’ humanized CD22 and CD74 antibodies given at American Society of Hematology (ASH) meeting

December 5, 2003

study shows that humanized antibody conjugated with radioiodine by a new, proprietary, method improves therapeutic effectiveness in human breast cancer model

-Presentation at 26th Annual San Antonio Breast Cancer Symposium-

November 20, 2003

Immunomedics’ bispecific antibody technology shows three-fold increase in radiation dose delivered to colon cancer model

November 20, 2003

Immunomedics reports on new drug candidate at cancer conference

November 13, 2003

Immunomedics announces first quarter fiscal 2004 results

Click here to download Condensed Consolidated Balance Sheets

November 11, 2003

Immunomedics in discussions to regain development rights from Amgen for Epratuzumab

November 7, 2003

Immunomedics announces publication of abstracts involving four product candidates on American Society of Hematology (ASH) website

October 23, 2003

Immunomedics’ subsidiary, IBC Pharmaceuticals, Inc., enters research collaboration with Schering Ag.

October 20, 2003

Immunomedics to present at the 5th annual Rodman & Renshaw Techvest Healthcare Conference

September 22, 2003

Immunomedics to present at UBS Global Life Sciences Conference

September 8, 2003

Immunomedics to present at the Bear Stearns 16th annual healthcare conference

August 21, 2003

Immunomedics reports continued progress on product development

August 13, 2003

Immunomedics announces fiscal 2003 results

June 25, 2003

Immunomedics reports results with proprietary diagnostic imaging product

June 24, 2003

Immunomedics reports on advances in cancer imaging products

June 23, 2003

Immunomedics reports progress in cancer therapy at 50th annual meeting of the Society of Nuclear Medicine

June 1, 2003

Immunomedics reports on two novel antibodies for B-cell tumor therapy

June 1, 2003

Anti-cea monoclonal antibody combined with chemotherapy demonstrates positive preclinical results in colon and breast cancers

May 28, 2003

Immunomedics completes NJEDA bond financing for large-scale manufacturing facility

May 12, 2003

Immunomedics to appeal patent infringement decision

May 8, 2003

Immunomedics reports fiscal third quarter 2003 results

May 6, 2003

Immunomedics awarded U.S. patent for improved method of labeling antibodies with iodine-131

April 21, 2003

IBC pharmaceuticals elects two distinguished scientists to board of directors

April 15, 2003

Immunomedics granted additional patent for proprietary treatment of infectious disease

April 9, 2003

CIS Bio International enters into a settlement with Immunomedics regarding CEA antibody technology

February 10, 2003

Immunomedics reports fiscal second quarter 2003 results

January 23, 2003

Amgen and Immunomedics announce emphasis on development of amg 412 (Epratuzumab) as combination therapy while closing single agent trial

January 15, 2003

Immunomedics’ scientists report on improved linker for yttrium isotope used with Epratuzumab in lymphoma therapy

January 3, 2003

Immunomedics, Inc. to present at 21st annual J.P. Morgan H∓Q Healthcare Conference